AGTC - Applied Genetic' stock surges on encouraging data from achromatopsia trials

Gene therapy company Applied Genetic Technologies' (AGTC) shares jump ~19% in after market trade after it posts promising additional data from its ongoing ACHMB3 and ACHMA3 clinical trials in patients with achromatopsia ((ACHM)), an inherited retinal disease.The company said that the additional data provides quantitative evidence of improvements in visual sensitivity that supports positive patient reported outcomes.AGTC's preliminary results are based on a patient-by-patient analysis of data from both ACHMB3 and ACHMA3 trials.The company expects to report 12 month data from adult patients in both trials in Q2 2021.Applied Genetic also said it expects to post preliminary 3-month data from the pediatric patients in both trials in Q4 2021.Applied Genetic had reported additional data from its ongoing Phase 1/2 study evaluating its gene therapy in patients with X-linked retinitis pigmentosa (XLRP), an inherited disorder affecting the retina that leads to vision loss, in November last year.

For further details see:

Applied Genetic' stock surges on encouraging data from achromatopsia trials